Methods: S. aureus TX0117, a type A Bla+ clinical isolate from a patient that failed CFZ therapy and TX0117-cured (TX0117c), a derivative of TX0117 which lacks β-lac activity, were used in a rat model of endocarditis. 1 animal per strain, in addition to historical controls (n=22), was sacrificed at the start of therapy to assess colony forming units (CFU) per gram of vegetation at T=0. CFZ 50 mg/kg alone (n=11) or CFZ 50 mg/kg plus CL 4 mg/kg (n=7) was given IM every 8 hours for 72 hours. Doses were selected to mimic mean serum concentration of standard doses (given IM (CFZ) or PO (CL)) in humans. Rats were sacrificed 16 hours after the last antibiotic dose, aortic valves were aseptically excised, weighed, homogenized in 1 ml of saline and the entire volume was plated in serial ten-fold dilutions on mannitol salt and/or brain heart infusion agar. Representative recovered colonies were tested for β-lac activity using nitrocefin. Comparisons of CFU between groups were done by the Mann-Whitney Wilcoxon unpaired test with significance at p<0.05.
Results: At baseline, there was no significant difference between the CFU/g of control animals infected with the two strains (TX0117 7.3±1.3 and TX0117c 7.89±0.83, mean log10±SD). Compared to untreated controls, the TX0117 group treated with CFZ alone had a reduction of 2±0.6 CFU/g, while the CFZ plus CL arm had a 7.1±0.5 CFU/g reduction, a statistically significant difference between the two arms (p=0.0002). CFZ treatment of the TX0117c strain lacking blaZ activity was similar to CFZ+CL (6.5±0.6 log10 CFU/g reduction, p<0.0001).
Conclusion: Against Bla+ TX0117, the addition of CL, at a dose mimicking human PO kinetics, restored the efficacy of CFZ and overcame the InE. This provides a proof-of-concept for the use of oral CL with CFZ when there is a concern for the InE.
C. Arias, None
B. Murray, None
See more of: Oral Abstract Session